Advances in Diagnostic Assays for Tuberculosis

Overview

Journal Cold Spring Harb Perspect Med

Specialty General Medicine

Date 2015 Aug 9

PMID 26253092

Citations 7

Authors

Stephen D Lawn

Affiliations

Soon will be listed here.

Abstract

Approximately one-third of the global burden of tuberculosis (TB) remains undiagnosed each year and the vast majority of cases of multidrug-resistant TB remain undetected. Many countries still place heavy reliance on outdated technologies that are blunt and ineffective tools for controlling this epidemic. However, during the past 10 years, there has been substantial progress within the TB diagnostics developmental pipeline. Old technologies have been reviewed and improved and new technologies have been developed and evaluated and are now being implemented. This review summarizes these developments and describes the currently available diagnostic tools. Consideration is given to the requirements of future diagnostic tests and how these should be evaluated not only with regard to their diagnostic accuracy and operational feasibility, but ultimately in terms of whether they impact clinical outcomes cost effectively, especially for those most in need.

Citing Articles

A Comprehensive Review of HIV-Associated Tuberculosis: Clinical Challenges and Advances in Management.

Patel A, Pundkar A, Agarwal A, Gadkari C, Nagpal A, Kuttan N Cureus. 2024; 16(9):e68784.

PMID: 39371702 PMC: 11456262. DOI: 10.7759/cureus.68784.

Advancements in Tuberculosis Diagnostics: A Comprehensive Review of the Critical Role and Future Prospects of Xpert MTB/RIF Ultra Technology.

Yadav S, Rawal G, Jeyaraman M, Jeyaraman N Cureus. 2024; 16(3):e57311.

PMID: 38690500 PMC: 11059844. DOI: 10.7759/cureus.57311.

Trends and challenges of multi-drug resistance in childhood tuberculosis.

Zhuang Z, Sun L, Song X, Zhu H, Li L, Zhou X Front Cell Infect Microbiol. 2023; 13:1183590.

PMID: 37333849 PMC: 10275406. DOI: 10.3389/fcimb.2023.1183590.

Accuracy of C-reactive protein and a differentiated white cell count in diagnosing tuberculosis.

Ruder G, Carter R, Joubert G S Afr J Infect Dis. 2023; 38(1):481.

PMID: 37293515 PMC: 10244949. DOI: 10.4102/sajid.v38i1.481.

An isothermal amplification-based point-of-care diagnostic platform for the detection of : A proof-of-concept study.

Shanmugakani R, Bonam W, Erickson D, Mehta S Curr Res Biotechnol. 2021; 3:154-159.

PMID: 34308334 PMC: 8301208. DOI: 10.1016/j.crbiot.2021.05.004.

References

Steingart K, Henry M, Laal S, Hopewell P, Ramsay A, Menzies D . A systematic review of commercial serological antibody detection tests for the diagnosis of extrapulmonary tuberculosis. Thorax. 2007; 62(10):911-8. PMC: 2094240. DOI: 10.1136/thx.2006.075754. View

Peter J, Theron G, van Zyl-Smit R, Haripersad A, Mottay L, Kraus S . Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J. 2012; 40(5):1211-20. PMC: 5523653. DOI: 10.1183/09031936.00201711. View

Steingart K, Dendukuri N, Henry M, Schiller I, Nahid P, Hopewell P . Performance of purified antigens for serodiagnosis of pulmonary tuberculosis: a meta-analysis. Clin Vaccine Immunol. 2008; 16(2):260-76. PMC: 2643545. DOI: 10.1128/CVI.00355-08. View

Bossuyt P, Reitsma J, Bruns D, Gatsonis C, Glasziou P, Irwig L . The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med. 2003; 138(1):W1-12. DOI: 10.7326/0003-4819-138-1-200301070-00012-w1. View

Phillips M, Basa-Dalay V, Blais J, Bothamley G, Chaturvedi A, Modi K . Point-of-care breath test for biomarkers of active pulmonary tuberculosis. Tuberculosis (Edinb). 2012; 92(4):314-20. DOI: 10.1016/j.tube.2012.04.002. View

Young D, Gideon H, Wilkinson R . Eliminating latent tuberculosis. Trends Microbiol. 2009; 17(5):183-8. DOI: 10.1016/j.tim.2009.02.005. View

Lawn S, Kerkhoff A, Vogt M, Wood R . Clinical significance of lipoarabinomannan detection in urine using a low-cost point-of-care diagnostic assay for HIV-associated tuberculosis. AIDS. 2012; 26(13):1635-43. DOI: 10.1097/QAD.0b013e3283553685. View

Crudu V, Stratan E, Romancenco E, Allerheiligen V, Hillemann A, Moraru N . First evaluation of an improved assay for molecular genetic detection of tuberculosis as well as rifampin and isoniazid resistances. J Clin Microbiol. 2012; 50(4):1264-9. PMC: 3318528. DOI: 10.1128/JCM.05903-11. View

Moore D, Evans C, Gilman R, Caviedes L, Coronel J, Vivar A . Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med. 2006; 355(15):1539-50. PMC: 1780278. DOI: 10.1056/NEJMoa055524. View

10.

Minion J, Leung E, Menzies D, Pai M . Microscopic-observation drug susceptibility and thin layer agar assays for the detection of drug resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2010; 10(10):688-98. DOI: 10.1016/S1473-3099(10)70165-1. View

11.

Talbot E, Munseri P, Teixeira P, Matee M, Bakari M, Lahey T . Test characteristics of urinary lipoarabinomannan and predictors of mortality among hospitalized HIV-infected tuberculosis suspects in Tanzania. PLoS One. 2012; 7(3):e32876. PMC: 3297608. DOI: 10.1371/journal.pone.0032876. View

12.

Lawn S, Mwaba P, Bates M, Piatek A, Alexander H, Marais B . Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis. 2013; 13(4):349-61. PMC: 4844338. DOI: 10.1016/S1473-3099(13)70008-2. View

13.

Lemaire J, Casenghi M . New diagnostics for tuberculosis: fulfilling patient needs first. J Int AIDS Soc. 2010; 13:40. PMC: 2987791. DOI: 10.1186/1758-2652-13-40. View

14.

Dowdy D, Gounder C, Corbett E, Ngwira L, Chaisson R, Merritt M . The ethics of testing a test: randomized trials of the health impact of diagnostic tests for infectious diseases. Clin Infect Dis. 2012; 55(11):1522-6. PMC: 3491859. DOI: 10.1093/cid/cis736. View

15.

Boehme C, Nabeta P, Hillemann D, Nicol M, Shenai S, Krapp F . Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010; 363(11):1005-15. PMC: 2947799. DOI: 10.1056/NEJMoa0907847. View

16.

Wallis R, Kim P, Cole S, Hanna D, Andrade B, Maeurer M . Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect Dis. 2013; 13(4):362-72. DOI: 10.1016/S1473-3099(13)70034-3. View

17.

Bruins M, Rahim Z, Bos A, van de Sande W, Endtz H, van Belkum A . Diagnosis of active tuberculosis by e-nose analysis of exhaled air. Tuberculosis (Edinb). 2012; 93(2):232-8. DOI: 10.1016/j.tube.2012.10.002. View

18.

Lawn S, Kerkhoff A, Burton R, Meintjes G . Underestimation of the incremental diagnostic yield of HIV-associated tuberculosis in studies of the Determine TB-LAM Ag urine assay. AIDS. 2014; 28(12):1846-8. DOI: 10.1097/QAD.0000000000000305. View

19.

Morgan M, Kalantri S, Flores L, Pai M . A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2005; 5:62. PMC: 1185540. DOI: 10.1186/1471-2334-5-62. View

20.

Drobniewski F, Nikolayevskyy V, Maxeiner H, Balabanova Y, Casali N, Kontsevaya I . Rapid diagnostics of tuberculosis and drug resistance in the industrialized world: clinical and public health benefits and barriers to implementation. BMC Med. 2013; 11:190. PMC: 3765611. DOI: 10.1186/1741-7015-11-190. View